[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342920-105":59,"doc-detail-342920-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","public-neoantigens-in-breast-cancer-immunotherapy-review-abstract-and-clinical-utilization-overview","Public neoantigens in breast cancer immunotherapy (Review) - Abstract and clinical utilization overview","","Breast cancer is the most prevalent cancer among women globally and a leading cause of cancer-related death. Although genetic mutations contribute to disease, most cases occur without a family history, indicating frequent sporadic mutations. In cancer genomics, neoantigen-based immunotherapy has emerged as a key approach, with novel proteins from somatic mutations enabling both individualized and public cancer treatment pathways. Shared public neoantigens can support “off-the-shelf” therapies, widening benefit across patient populations.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/public-neoantigens-in-breast-cancer-immunotherapy-review-abstract-and-clinical-utilization-overview/342920/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/public-neoantigens-in-breast-cancer-immunotherapy-review-abstract-and-clinical-utilization-overview/342920.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"How does the review position neoantigen-targeted immunotherapy compared with private neoantigens?","Question",{"text":113,"@type":114},"The review notes that most prior neoantigen studies focus on private, patient-specific neoantigens, which are time-consuming and costly. Shared or public neoantigens may allow broader use and cost savings in breast cancer treatment.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},342920,1790560359,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":132,"language":133,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":134,"faqs":135,"seo_title":136,"seo_description":67,"update_tm":137,"read_time":138,"preview_page_count":19,"preview_urls":139},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE 54: 65, 2024  \nPublic neoantigens in breast cancer immunotherapy (Review)  \nNATTHAPORN SUEANGOEN 1,2 , PETI THUWAJIT2 ,  \nPA‑THAI YENcHITSOMANUS3,4 and cHANITRA THUWAJIT2  \n1 2  \nResearch center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand; department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; 3Siriraj center of Research Excellence for cancer  \nImmunotherapy (SicORE‑cIT), Research department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; 4  \ndivision of Molecular Medicine, Research department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand  \nReceived January 17, 2024; Accepted May 15, 2024  \ndOI: 10.3892/ijmm.2024.5388  \nAbstract. Among women globally, breast cancer is the most prevalent cancer and the leading cause of cancer‑related death. Interestingly, though genetic mutations contribute to the disease, \u003C15% of women diagnosed with breast cancer have a family history of the disease, suggesting a prevalence of sporadic genetic mutations in breast cancer development. In the rapidly rising field of cancer genomics, neoantigen‑based immunotherapy has come to the fore. The investigation of novel proteins arising from unique somatic mutations or neoantigens have opened a new pathway for both individualized and public cancer treatments. Because they are shared among individuals with similar genetic changes, public neoantigens provide an opportunity for ‘off‑the‑shelf’ anticancer therapies, potentially extending the benefits to a wider patient group. The present review aimed to highlight the role of shared or public neoan‑ tigens as therapeutic targets for patients with breast cancer, emphasizing common hotspot mutations of certain genes identified in breast cancer. The clinical utilization of public neoantigen‑based therapies for breast cancer treatment were also discussed.  \nContents  \n1. Introduction  \n2. Breast cancer incidence, classification and management  \n3. Tumor antigens  \n4. Genetic mutations associated with breast cancer development  \nCorrespondence to: Professor chanitra Thuwajit, department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wang Lang Road, Bangkok Noi, Bangkok 10700, Thailand  \nE‑mail: [cthuwajit@yahoo.com](cthuwajit@yahoo.com)  \nKey words: breast cancer, hotspot mutation, immunotherapy, public neoantigen  \n5. Mutational landscape in breast cancer  \n6. Neoantigen landscape in breast cancer  \n7. clinical utilization of public neoantigens for breast cancer treatment  \n8. conclusion  \n1. Introduction  \nBreast cancer, the most frequently diagnosed cancer in women globally, accounted for up to 2 million new cases in recent years, making up 25% of all cancer cases in women (1) . The complexity of breast cancer is highlighted by its high degree of heterogeneity, with current classifications based on three molec‑ ular markers: The estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) (2) . Therapeutic approaches and outcomes differ significantly among the various subtypes of breast cancer. The ER‑negative (ER‑) group, which includes the HER2‑positive (HER2+) and triple‑negative breast cancer (TNBc) subtypes, is less responsive to neoadjuvant chemotherapy compared with the ER‑positive (ER+) group (3,4) .  \nIn the past decades, numerous studies utilizing genome sequencing of breast cancers have revealed increasing numbers, up to thousands, of somatic mutations during the onset and progression of cancer (5) . However, only a minor proportion of these mutations inherently provide a growth advantage to cancer cells, and are referred to as ‘driver mutations’ (6) . Some of the driver mutations frequently observed in a particular dNA segment are known as ‘hotspot mutations’ and serve as targets for diagnosis and drug developmen","cbCaij0YubrOr9To","https://ap.wps.com/l/cbCaij0YubrOr9To","pdf",1900239,14,"English","# Contents\n## Introduction\n## Breast cancer incidence, classification and management\n## Tumor antigens\n## Genetic mutations associated with breast cancer development\n## Mutational landscape in breast cancer\n## Neoantigen landscape in breast cancer\n## Clinical utilization of public neoantigens for breast cancer treatment\n## Conclusion","[{\"question\":\"How does the review position neoantigen-targeted immunotherapy compared with private neoantigens?\",\"answer\":\"The review notes that most prior neoantigen studies focus on private, patient-specific neoantigens, which are time-consuming and costly. Shared or public neoantigens may allow broader use and cost savings in breast cancer treatment.\"}]","Public neoantigens in breast cancer immunotherapy (Review) - Abstract and clinical utilization overview | PDF",1790048858,35,[140,144,148,152],{"page_no":8,"url":141,"width":142,"height":143},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7aec1726b3714690a6135d0a7171bb1d.webp",983,1357,{"page_no":14,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84326f58be1d7e1aa118a900df143e08.webp",982,1356,{"page_no":81,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d14b4017ed594e134a0c038a7b8f9ae4.webp",981,1354,{"page_no":19,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1eab4b740ab8e29fdece540f6bd6dbb4.webp",980,1353]